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Objective: We sought to replicate a previously published prediction model for pro-
gression, developed in the Cache County Dementia Progression Study, using a clinical
cohort from the National Alzheimer's Coordinating Center.
Methods: We included 1120 incident Alzheimer disease (AD) cases with at least
one assessment after diagnosis, originating from 31 AD centres from the United
States. Trajectories of the Mini‐Mental State Examination (MMSE) and Clinical
Dementia Rating sum of boxes (CDR‐sb) were modelled jointly over time using paral-
lel‐process growth mixture models in order to identify latent classes of trajectories.
Bias‐corrected multinomial logistic regression was used to identify baseline predictors
of class membership and compare these with the predictors found in the Cache
County Dementia Progression Study.
Results: The best‐fitting model contained 3 classes: Class 1 was the largest (63%)
and showed the slowest progression on both MMSE and CDR‐sb; classes 2 (22%)
and 3 (15%) showed moderate and rapid worsening, respectively. Significant predic-
tors of membership in classes 2 and 3, relative to class 1, were worse baseline MMSE
and CDR‐sb, higher education, and lack of hypertension. Combining all previously
mentioned predictors yielded areas under the receiver operating characteristic curve
of 0.70 and 0.75 for classes 2 and 3, respectively, relative to class 1.
Conclusions: Our replication study confirmed that it is possible to predict trajecto-
ries of progression in AD with relatively good accuracy. The class distribution was
comparable with that of the original study, with most individuals being members of
a class with stable or slow progression. This is important for informing newly diag-
nosed AD patients and their caregivers.
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1 | INTRODUCTION
Alzheimer disease (AD) is a very heterogeneous condition, in terms of
both its presentation and its progression.1,2 Upon diagnosis, questions
regarding future speed of decline may arise, which are difficult to
answer owing to the large variation in disease course within and
between patients. Moreover, different areas of functioning can be
affected in AD patients: Whereas some develop mainly cognitive com-
plaints, others show rapid decline in daily functioning as well.3 As a
consequence, patients, families, and physicians face considerable
uncertainty regarding disease prognosis.
So far, only a limited number of studies have attempted to unravel
the heterogeneity in AD progression.4 Most of these studies looked at
one health dimension at a time (eg, cognition), even though the impor-
tance of a multidomain approach in dementia has been repeatedly
reinforced.3,5,6 The few studies that have analysed multiple outcomes
of AD simultaneously have shown correlation between rates of
change in cognition and daily functioning.2,7,8
A literature review of factors associated with rapid cognitive
decline in AD concluded that study results were heterogeneous and
often contradictory. The review showed that studies are often limited
in terms of sample size, duration of follow‐up, or both. Moreover, the
definition of rapid decline in AD varies across studies, and cut‐offs are
often arbitrarily chosen. Overall, younger patients with higher educa-
tion and more cognitive impairment at baseline appear to decline more
rapidly.9 Other studies have shown AD progression is likely to be influ-
enced by noncognitive factors, such as depressive symptoms and co‐
morbid disease burden as well.6,7 These findings suggest that combining
disease‐related characteristics with other information on the patient's
profilemay improve the prediction of AD progression. Such a prediction
may not only provide valuable prognostic information for patients and
caregivers but also help us to target patients who are most likely to
benefit from interventions aimed at slowing disease progression.
In an attempt to increase our knowledge on the course of AD and
its predictors, a prediction model based on data from the Cache County
Dementia Progression Study (CCDPS) identified 4 different classes of
cognitive and functional progression, with cognitive status at the
moment of diagnosis being the strongest predictor of future decline.8
Although replication is pivotal in prognostic factor research,10 these
findings have not been replicated yet. In the present study, we sought
to replicate the prediction model from the CCDPS in a large clinical
cohort from the National Alzheimer's Coordinating Center (NACC).
The aims of this study are (1) to identify latent classes of trajectories
of AD progression and (2) to predict class membership using AD‐related
and other characteristics of the patient.
2 | MATERIALS AND METHODS
2.1 | Sample description
Data from the NACC Uniform Data Set were used. This database
consists of a referral/volunteer‐based case series of AD patients from
AD centres (ADCs) throughout the United States who are followed up
yearly.We included 1120 incident AD caseswith at least one assessment
after diagnosis. Standardized criteria for the diagnosis of AD were used
across the ADCs.11 An AD incident case was defined as having a study
visit at which the patient was deemed free of AD within 18months prior
to diagnosis and a global Clinical Dementia Rating (CDR) ≤ 1 at the
moment of diagnosis. This analysis used data from 31 ADCs, with visit
dates ranging from June 2006 through the December 2015 data freeze.
A detailed description of the NACC data can be found elsewhere.12
2.2 | Measures of AD progression
We used the Mini‐Mental State Examination (MMSE) score to assess
cognition.13 This is a global score of cognitive abilities ranging from
0 to 30, with higher scores indicating better cognitive performance.
The CDR sum of boxes (CDR‐sb) was used to assess daily function-
ing.14 This scale measures global cognitive and functional abilities
and ranges from 0 to 18, with higher scores indicating more severe
impairment. To enhance comparability and interpretation of our
model, CDR‐sb scores were reverse‐coded ranging up to 30, so higher
scores indicated better performance (eg, a CDR‐sb score of 1 was
recoded as 29). Data across the first 3 years after diagnosis were used.
2.3 | Independent variables
The following variableswere included as potential predictors of progres-
sion: age; gender; race (white vs other); education (years); time since first
symptoms; MMSE13 and CDR‐sb14 scores; and history of transient isch-
aemic attack (yes/no), history of hypertension (yes/no), Neuropsychiat-
ric Inventory Questionnaire total score (range: 0‐36, with higher values
indicating more symptoms),15 and its subdomains: psychosis (delusions
or hallucinations: yes/no), depression or dysphoria (yes/no), and apathy
or indifference (yes/no). We used information obtained at baseline,
which corresponds to the moment of diagnosis in the present analysis.
2.4 | Statistical analyses
We used parallel‐process growth mixture models (GMMs) to model tra-
jectories of MMSE and CDR‐sb jointly over time.8 The GMMs allow for
grouping of subjects into so‐called latent classes, on the basis of simi-
larities in their progression patterns over time.16 This means an increas-
ing number of curves is fit until an optimal balance between model fit
Key points
• Heterogeneity in Alzheimer disease (AD) progression
causes uncertainty regarding prognosis for patients,
families, and physicians.
• We identified 3 classes with distinct rates of cognitive
and functional decline using growth mixture modelling.
• The majority of AD patients showed a slower
progression as compared with the mean population
trajectory, which is typically reported.
• Predictors of dementia course include education,
hypertension, and cognitive and functional status at
diagnosis.
1058 HAAKSMA ET AL.
and model complexity is reached. The GMMs are a longitudinal form of
latent class analysis, in which mixed models are used. A specific type of
GMMs, termed parallel‐process GMM, allowed us to model 2 out-
comes simultaneously over time. We fit quadratic models with 1 to 5
classes and chose our final model on the basis of the Bayesian informa-
tion criterion (BIC), Lo‐Mendell‐Rubin (LMR) likelihood ratio test, and
class sizes.17 The BIC is an indicator of model fit, with lower values
indicating better model fit. The LMR test compares the improvement
in model fit between 2 nested models. A significant LMR test denotes
that the model with k classes fits better than did the same model with
k − 1 classes.18 Maximum likelihood estimation was used to obtain
parameter estimates, with standard errors (SEs) that are robust to
nonnormality. Observations were assumed to be spaced exactly 1 year
apart. The variance of the quadratic slope was fixed to 0. The residual
variances were allowed to vary over time and were assumed to be
equal across classes. After the number of classes has been decided,
multinomial logistic regression with the 3‐step method was used to
examine which factors predicted class membership in a multivariable
model.19 Continuous predictors were mean‐centred. The area under
the curve (AUC), a measure of classification utility, was subsequently
calculated for sets of predictors via receiver operating characteristic
(ROC) curves. The GMMs, including multinomial logistic regression
models, were fit using Mplus version 8.20 Further analyses, including
ROCs and processing of results, were performed using R v. 3.2.4.21
2.5 | Comparison with Cache County model
The model, which we aimed to replicate, was based on data from 328
incident AD patients of the population‐based CCDPS.8 It used the
same diagnostic criteria, AD progression measures, independent vari-
ables, and statistical methods as described in the previous paragraphs.
In contrast to the present study, however, the sample of the CCDPS
was population‐based. Four classes of quadratic trajectories were
identified, with the majority of the sample (72%) belonging to class 1
with the slowest progression. Classes 2 to 4 each contained 8% to
11% of the sample and showed more rapid declines in both cognition
and daily functioning. In the multivariable regression model, only
MMSE score at diagnosis was identified as a significant predictor for
class membership. Higher MMSE scores at diagnosis were associated
with a decreased chance of being a member of more rapidly declining
classes. The AUCs for the multivariate model were 0.98, 0.88, and
0.67, respectively, for classes 2 to 4 (with class 1 as the reference).
We aimed to replicate the latent classes from the CCDPS by
modelling these 4 classes in our sample from the NACC, using the pre-
viously published parameter estimates. The goodness‐of‐fit of this
model was subsequently compared with a 4‐class model with uncon-
strained parameter estimates to determine whether a comparable
model would be obtained in the absence of prior knowledge from
the CCDPS. A chi‐square difference test based on log‐likelihood
values and scaling correction factors was used for this comparison.
3 | RESULTS
3.1 | Sample characteristics
Baseline characteristics (from the moment of AD diagnosis) of our
sample are summarized in Table 1. The mean age at diagnosis was
TABLE 1 Sample characteristics: mean (SD) or % [count]
Characteristics Baseline 1st Follow‐up 2nd Follow‐up 3rd Follow‐up
N 100 [1120] 100 [1120] 60.8 [681] 34.1 [382]
MMSE score 24.2 (3.2) 22.3 (4.5) 20.8 (5.1) 19.0 (6.2)
CDR‐sb 3.8 (1.6) 5.6 (2.9) 7.0 (3.5) 8.5 (4.2)
Follow‐up time, y NA 1.2 (0.5) 2.2 (0.5) 3.3 (0.7)
Age at diagnosis 79.4 (8.7)
Gender: female 52.1 [584]
Race
White 86.7 [968]
Black or African American 9.5 [106]
Asian 2.2 [24]
Unspecified 1.6 [22]
Time since first symptoms, y 5.5 (2.9)
Education, y 15.4 (3.2)
NPI‐Q
Severity score 3.6 (3.7)
Psychosis 9.6 [104]
Depression or dysphoria 37.4 [406]
Apathy or indifference 36.3 [395]
History of transient ischaemic attack 8.1 [90]
History of hypertension 62.8 [703]
Abbreviations: CDR‐sb, Clinical Dementia Rating—sum of boxes (range, 0‐18, higher = worse); MMSE, Mini‐Mental State Examination (range, 0‐30,
higher = better); N, number of participants in whom at least 1 of 2 outcomes was measured; NA, not applicable; NPI‐Q, Neuropsychiatric Inventory Ques-
tionnaire severity score (range, 0‐36, higher = worse); SD, standard deviation.
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79.4 years, with a range of 45.3 to 103.0. The majority of the
sample was female (52.1%), and the mean follow‐up time since
diagnosis was 2.6 years. Three years after diagnosis, 103 patients
had died (9.2%). The mean MMSE score at diagnosis was 24.2, and
the mean CDR‐sb was 3.8.
3.2 | Heterogeneity of progression
Quadratic curves for MMSE and CDR‐sb progression were fit across
the first 3 years after diagnosis. The observed individual trajectories
of MMSE and CDR‐sb and means of the entire sample are depicted in
Figure 1A. The observed variation in the intercept and the slope was
found to be significant, allowing for the identification of latent classes
of progression, as described in the next paragraph. Trajectories of
MMSE and CDR‐sb were clearly related, as shown by the strong
correlation between their random slopes (R = 0.92, P < .001).
3.3 | Latent classes of progression
When fitting models with increasing numbers of classes, the 3‐class
model provided the best fit according to the LMR test (3‐ vs 4‐class
model: −2LL(7) = 119.31, P = .565) and the class sizes. An overview
of the model fit criteria is shown inTable 2. When increasing the num-
ber of classes beyond 3, the smallest class contained only 2% of our
sample, indicating that a model with more than 3 classes derived from
our sample is unlikely to be replicated. The difference in BIC between
the 3‐class model and the 4‐class model is also rather small, indicating
the model fit improvement caused by the 4th class was minimal.
The best‐fitting model included class‐specific intercept variances
and class‐specific slope variances. The parameter estimates of this 3‐
class model are shown in Table 3, and the trajectories are depicted in
Figure 1B‐D. Class 1 was the largest (63%) and showed the best
cognitive and functional abilities at diagnosis, as well as the slowest
decline. Class 2 was the second largest class (22%), showing some-
what decreased cognitive and functional abilities at diagnosis, as well
as a quadratic decrease of abilities over time. Class 3 was the smallest
(15%), showing somewhat decreased cognitive and functional abilities
at diagnosis, as well as dramatic worsening over time.
3.4 | Predictors of class membership
All potential predictors of class membership listed inTable 1 were exam-
ined using multivariable logistic regression, with predicted class
FIGURE 1 Fitted and observed MMSE and CDR‐sb trajectories. MMSE trajectories are shown in red. CDR‐sb trajectories are shown in blue.
CDR‐sb scores were reverse‐coded ranging up to 30 (higher = better). A, The trajectories of the entire sample (N = 1120). The identified latent
classes are presented in bottom row of the figure. B, The slowly progressing class 1 (N = 778). C, Class 2 (N = 169) with moderate progression
speed. D, The rapidly progressing class 3 (N = 173). The mean trajectories of each plot are shown in bold. Individuals were assigned to classes on
the basis of their most likely class membership, causing the class counts to slightly differ from those in the text and Table 3, which were based on
the probability of class membership. CDR‐sb indicates Clinical Dementia Rating—sum of boxes; MMSE, Mini‐Mental State Examination score
[Colour figure can be viewed at wileyonlinelibrary.com]
TABLE 2 Overview of class enumeration
No.
Classes
No.
Parametersa BIC Entropy
LMR P
Value
Smallest Class
Size, %
1 24 29 173.68 … … …
2 31 28 877.56 0.919 .000 9
3 38 28 732.35 0.748 .007 10
4 45 28 662.18 0.772 .565 2
5 52 28 609.51 0.778 .014 2
Abbreviations: BIC, Bayesian information criterion (lower values imply bet-
ter model fit); Entropy, higher values imply better classification quality;
LMR, Lo‐Mendell‐Rubin likelihood ratio test.
aThe process of class enumeration was based on models with class‐invari-
ant random intercept and random slope.
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membership in our final 3‐class model as dependent variable. Table 4
shows the significant predictors of class membership, corrected for
age, gender, and time since first symptoms. This analysis was based on
1008 patients; 112 patients (10%) were excluded owing to missing
values for covariates. Significant predictors of membership in class 2, rel-
ative to class 1, were worse baseline CDR‐sb, higher education, and lack
of hypertension. Significant predictors of membership in class 3, relative
to class 1, wereworseMMSE andCDR‐sb at diagnosis. For example, a 1‐
point higher MMSE score (reflecting better cognitive functioning) at
diagnosis reduces the risk of membership in the rapidly declining class
3 by 15%, relative to class 1 (OR = 0.85, 95% CI, 0.79‐0.92, P < .001).
Combining all significant predictors of class membership yielded
AUCs of 0.70 and 0.75 for classes 2 and 3, relative to class 1.
Figure 2 shows ROC curves for successively larger sets of predictors.
The AUC increased when more predictors were added.
3.5 | Replication of the Cache County model
When comparing the previously published 4‐class model (using the
parameter estimates from the CCDPS as constraints) with an uncon-
strained 4‐class model in our sample from the NACC, the chi‐square
test indicated that the unconstrained model fit the data better
(χ2(24) = 706.70, P < .001). When constraining the model parameters
to be equal to those from the 4‐class Cache County model, 2 of 4
classes contained very few patients (class prevalence < 0.02). These
TABLE 3 Parameter estimates for MMSE and CDR‐sb trajectories by latent class
Class 1
Slow Progression
Class 2
Moderate Progression
Class 3
Rapid Progression
Prevalence (% [N]a) 63 [702] 22 [243] 15 [175]
Mean (SE) Mean (SE) Mean (SE)
Fixed effects
Intercept MMSE 24.60 (0.18)b 24.13 (0.53)b 22.53 (0.39)b
CDR‐sbc 26.52 (0.07)b 25.78 (0.19)b 25.24 (0.14)b
Linear annual rate of decline MMSE −0.67 (0.18)b −1.06 (0.57) −6.37 (0.93)b
CDR‐sbc −0.84 (0.09)b −0.17 (0.54) −6.55 (0.57)b
Quadratic annual rate of decline MMSE −0.21 (0.06)b −1.22 (0.29)b 0.45 (0.43)
CDR‐sbc −0.06 (0.04) −1.15 (0.26)b 1.04 (0.19)b
Random effects
Intercept variance MMSE 5.18 (0.67)b 5.73 (1.69)b 12.02 (3.45)b
CDR‐sbc 1.71 (0.17)d 2.09 (0.34)b 1.54 (0.28)b
Linear slope variance MMSE 0.54 (0.25)b 2.54 (0.48)b 9.82 (2.75)b
CDR‐sbc 0.44 (0.14)b 0.99 (0.25)b 4.51 (0.92)b
Residual variance at baseline MMSE 3.67 (0.46)b 3.67 (0.46)b 3.67 (0.46)b
CDR‐sbc 0.56 (0.14)b 0.56 (0.14)b 0.56 (0.14)b
Residual variance at 1st follow‐up MMSE 4.22 (0.39)b 4.22 (0.39)b 4.22 (0.39)b
CDR‐sbc 1.16 (0.14)b 1.16 (0.14)b 1.16 (0.14)b
Residual variance at 2nd follow‐up MMSE 4.72 (0.62)b 4.72 (0.62)b 4.72 (0.62)b
CDR‐sbc 2.23 (0.28)b 2.23 (0.28)b 2.23 (0.28)b
Residual variance at 3rd follow‐up MMSE 6.76 (1.21)b 6.76 (1.21)b 6.76 (1.21)b
CDR‐sbc 1.95 (0.64)d 1.95 (0.64)d 1.95 (0.64)d
Abbreviations: CDR‐sb, Clinical Dementia Rating—sum of boxes; MMSE, Mini‐Mental State Examination score; SE, standard error.
aN was based on the final class counts of the estimated model. Note that individuals are in fact assigned a probability of class membership.
bP < .001.
cCDR‐sb scores were reverse‐coded, ranging up to 30 (higher = better).
dP < .01.
TABLE 4 Odds ratios (ORs) from multivariate prediction of class membership (N = 1008)a
Class 2: Moderate Progression Class 3: Rapid Progression
OR (95% CI) P Value OR (95% CI) P Value
Age 0.98 (0.95‐1.02) .353 1.03 (1.00‐1.06) .088
Gender: male 0.69 (0.34‐1.43) .320 0.71 (0.42‐1.19) .193
Time since first symptoms 1.00 (0.87‐1.13) .942 0.94 (0.84‐1.05) .269
MMSE score 0.98 (0.90‐1.11) .969 0.85 (0.79‐0.92) <.001
CDR‐sbb 0.40 (0.28‐0.58) <.001 0.51 (0.42‐0.62) <.001
Education 1.19 (1.11‐1.28) .015 1.05 (0.97‐1.14) .190
History of hypertension 0.41 (0.21‐0.82) <.001 0.66 (0.40‐1.10) .113
aBold estimates are significant at P < .05. Reference is class 1.
bCDR‐sb scores were reverse‐coded (higher = better).
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results show we were unable to replicate the exact class structure
identified in the CCDPS.
4 | DISCUSSION
This study identified 3 latent classes of progression in AD, with the
majority (63%) of the patients being members of a class with steady
and slow progression, expecting to lose 3.9 MMSE points and 3.1
CDR‐sb points during the 3 years following diagnosis. At diagnosis,
an individual's class membership could be predicted with relatively
good accuracy (AUC = 0.70‐0.75) on the basis of their MMSE, CDR‐
sb, education, and history of hypertension. The difference between
the rates of change in the classes of our GMM (Figures 1B‐D) and
the population mean rate of change (Figure 1A) is substantial. Accord-
ing to the population mean, patients are expected to lose 7.9 MMSE
points and 5.9 CDR‐sb points during the 3 years following diagnosis.
The fact that most patients (63%) decline considerably less indicates
the need to look beyond the population mean and underlines the
importance of acknowledging subpopulations when clinicians try to
make prognoses for their AD patients. Similarly, researchers should
take into account the possibility of subgroups when studying decline
in AD. Inferences based on the mean trajectory of a population may
lead to serious overestimations of progression speed, as most patients
declined considerably less than average. It is therefore crucial for
future research to take into account subgroups of patients when
analysing the course of AD, which can, for example, be done by using
a GMM. Previous studies have already shown how the GMM approach
can aid the identification of preclinical AD patients in a cohort of cog-
nitively normal older adults.22-24 The present study shows the GMM
approach can also provide valuable insight into AD progression after
diagnosis, a topic that is studied far less often.
In our study, worse MMSE and CDR‐sb scores at diagnosis
appeared predictive of more rapid AD progression, as did higher educa-
tion. The latter may be caused by a delay in diagnosis due to cognitive
reserve, leading to more rapid decline after diagnosis as a consequence
of a more advanced disease stage.25 Having a history of hypertension
was associated with a reduced progression rate, ie, a reduced likelihood
of being a member in class 2, relative to class 1, OR (95% CI) = 0.41
(0.21‐0.82). This may be counterintuitive, however, having a history
of hypertension is likely to coincide with antihypertensive use, which
was previously found to be associated with decreased rate of decline
in AD and may offer a possible explanation.26
Although the identified classes in the present study are different
from those identified in the CCDPS, the finding that the majority of
the patients is a member of the class with relatively slow disease
progression is consistent across cohorts.8 According to the Cache
County model, 72% of the patients had an expected loss of 3.7
MMSE points and 2.0 CDR‐sb points at 3 years after diagnosis,
which resembles our findings. The fourth class identified in the
CCDPS also strongly resembles the third class of our model, with
an expected loss of 15.1 and 16.2 MMSE points, and 10.3 and
11.3 CDR‐sb points at 3 years, and a class prevalence of 15% and
8% in NACC and CCDPS, respectively. Furthermore, a strong corre-
lation between cognitive and functional decline was observed in
both cohorts (R = 0.92 in NACC and R = 0.91 in CCDPS), and this
is consistent with other studies as well.7,27-29 A study investigating
the temporal ordering of cognitive and functional decline in 2 differ-
ent cohorts showed that cognitive decline appears to precede and
predict functional decline in AD.30 These findings indicate that while
cognitive complaints worsen, patients also experience more limita-
tions in their daily functioning. In both the NACC and the CCDPS,
the MMSE score at diagnosis was a strong predictor of future pro-
gression. Differences in the identified classes in the NACC and the
CCDPS are likely due to differences in study population. Whereas
the CCDPS is a population‐based study from a single county in
northern Utah, the NACC cohort is a clinical cohort, consisting of
referral/volunteer‐based case series from multiple ADCs across the
United States. Moreover, the CDR‐sb was measured on a 5‐point
scale in CCDPS, while the NACC used a 3‐point scale, and patients
in the CCDPS were followed up every 6 months, while NACC partic-
ipants were followed up yearly. These differences may have caused
small changes in progression to remain undetected in the NACC
cohort. Interestingly, a recent study of cognitive and functional
FIGURE 2 Receiver operating characteristic curves for successive sets of predictors of latent class membership. Green = education.
Blue = education and MMSE. Red = education, MMSE, and CDR‐sb. Purple = education, MMSE, CDR‐sb, and hypertension. AUC indicates area
under the curve; CDR, Clinical Dementia Rating; MMSE, Mini‐Mental State Examination score [Colour figure can be viewed at wileyonlinelibrary.com]
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trajectories in a sample of 331 Dutch dementia patients also found 3
classes of progression, with similar patterns of decline.29
Unfortunately, studies investigating trajectories of multiple
dementia domains simultaneously are rare; however, there are several
studies that have identified classes of trajectories on the basis of a sin-
gle outcome. For example, a study by Wilkosz et al, focussing solely on
MMSE trajectories in a sample of 201 AD patients from Pittsburgh
(United States), found a strong relationship between psychosis at base-
line and more rapid cognitive decline.31 We did not find a similar asso-
ciation, possibly owing to the low prevalence of psychosis (9.6%) in our
sample. Across a period of 13.5 years, 6 classes of progression were
identified by Wilkosz et al, some of which did not appear to differ clin-
ically.31 This may be the result of using the BIC as the only criterion for
class enumeration. For this reason, we based our model on the agree-
ment of at least 2 model fit criteria (the LMR likelihood ratio test and
class size). On the basis of a large cohort (N = 3441) derived from UK
electronic health records, Baker et al. identified 6 different trajectories
of MMSE progression as well.32 Unfortunately, this study did not strat-
ify patients on the basis of their moment of dementia onset or diagno-
sis. Consequently, the observed heterogeneity may be largely
attributable to differences in disease stage at baseline, hampering infer-
ences about the progression of AD and its predictors. Our results agree,
in part, with a recent longitudinal study from Norway by Eldholm
et al.33 Similar to our finding that the majority of AD patients pro-
gresses relatively slowly, this study showed that approximately half of
their sample consisted of slow progressors, defined as showing less
than 1 point worsening in CDR‐sb per year. As in our study, the slow
progressors from the Norwegian cohort scored better on cognitive
tests and the CDR‐sb at diagnosis, than did the more rapid progressors.
In contrast to our findings, the intermediate and rapid progressors in
this study had fewer years of education than had the slow progressors.
It should be noted that the study by Eldholm et al included only a single
follow‐up measurement after a mean follow‐up time of 2 years, and its
sample consisted of both AD and MCI patients.33
The strengths of the present study include its large sample of
patients with a clinical diagnosis of AD and the inclusion of both cog-
nitive and functional measures of AD progression, reflecting the mul-
tidimensional impact of AD. In addition, the use of GMMs allowed
us to compare non‐linear change rates across subpopulations, without
using an arbitrary cut‐off for rapid decline. It has been shown that lin-
ear progression cannot simply be assumed in AD.34 The GMMs thus
enabled us to better assess correlations between progression
measures and their rates of change, as compared with studies using
correlations between linear rates of change.35
Limitations of our study include the use of single, relatively crude
measures of cognition (MMSE) and functioning (CDR‐sb), which may
not have captured subtle changes in progression. To correct for more
subtle differences in cognitive ability, we also included educational
attainment in our model. It should be noted that the CDR‐sb also con-
tains questions relating to cognition, whichmay, in part, have driven the
correlation with MMSE. Yet the CDR‐sb does provide an extra dimen-
sion to our operationalization of AD, as compared with looking merely
at MMSE. As the exact moment of AD onset is often unknown, one
could wonder to what extent differences in baseline MMSE and CDR‐
sb scores across our classes reflect differences in disease stage. The
difficulty of synchronization of AD onset is widely recognized in AD tra-
jectory studies.36,37 To minimize the differences in disease stage in our
sample, we used a strict definition of AD incidence in which patients
had to be deemed free of AD within 18 months prior to diagnosis and
had a global CDR ≤ 1 at the moment of diagnosis. In addition, we
corrected for time since first symptoms in our multinomial logistic
regression model. Despite these efforts to correct for possible differ-
ences in disease stage, it is possible that patients in the slowly declining
class, as compared with those in the other 2 classes, presented at the
clinic in an earlier stage of their disease, which may partly explain the
observed heterogeneity of decline. Another drawback is the lack of
additional relevant determinants of progression in the NACC data, such
as a patient's social network and co‐morbidity burden.
To our knowledge, this study is the first multidomain trajectory
analysis including over 1000 incident AD patients. In accordance with
previous studies,8,29 the majority of patients in our study showed sta-
ble and slow disease progression, considerably more optimistic than
the population mean trajectory. Moreover, we confirmed that it is pos-
sible to predict trajectories of progression in AD with acceptable accu-
racy. These findings are important for informing newly diagnosed
patients and their caregivers about the course of AD, especially given
the large uncertainty regarding prognosis, which they are currently
facing. These results are also important for informing clinical trials
intended to slow AD progression. Targeting those patients who are
specifically prone to decline rapidly will increase the chance to detect
statistically significant effects of beneficial interventions.38 Future
research should focus on identifying additional modifiable determi-
nants of AD progression in order to better characterize the large
patient group with a relatively mild disease course.
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